Hikma Pharmaceuticals Share News (HIK)

Earnings, Trading Statements Calendar - Week Ahead

London close: UK equities close week lower after non-farms, BoE's 'Super Thursday'

(ShareCast News) - A worse-than-expected US non-farm payrolls report and the Bank of England's downward revision to inflation estimates dragged UK equities lower at close of trading on Friday. The US added 215,000 jobs in July, falling short of forecasts of 225,000, according to the Labor Department

London open: UK stocks decline ahead of US non-farm payrolls

(ShareCast News) - UK stocks were in the red on Friday as investors continued to process news from the Bank of England and look ahead to the all-important US non-farm payrolls report. BoE Governor Mark Carney on Thursday said the timing of a first interest rate hike was drawing closer but the exact

Broker tips: Greene King, Hikma Pharmaceuticals

(ShareCast News) - Goldman Sachs reinstated its 'buy' rating on Greene King with a 1,060p price target, saying it expects the company to deliver consistent earnings growth given its exposure to accelerating UK consumer discretionary spending, execution of synergies post its Spirit acquisition and in

FTSE 100 movers: GSK and Hikma lead blue chips higher

(ShareCast News) - The FTSE 100 index built an early lead on Wednesday and stayed in positive territory thanks to forecast-busting results from several heavyweights in the pharma, tobacco and banking sectors. London's blue chip index was up 0.57% to 6,592.54 at 1435 BST. Top of the leaderboard mid-

Jefferies ups Hikma to 'buy', says Roxane deal is a "game changer"

(ShareCast News) - Hikma Pharmaceuticals got a boost after Jefferies upgraded the stock to 'buy' from 'hold' and raised its price target to 2,615p from 2,134p as it integrates the company's "transformational" deal with Roxane Laboratories. "In our view Hikma is transitioning to a period of remarkabl

LONDON MARKET MID-MORNING: Stocks Rise Driven By UK Company Updates

WINNERS & LOSERS SUMMARY: Barclays Up As It Outlines Scale-Down Plans

BUZZ-Hikma: Jefferies' EMEA darling after Boehringer deal

** Hikma Pharmaceuticals up c.3.9pct, top FTSE-100 gainer & adds to huge gains from a day earlier after brokerage Jefferies terms it its preferred name in the EMEA generics sector ** Brokerage bumps up stock to buy from hold and raises TP to 2615p from 2134p ** 8 of 13 brokerages rate

BROKER RATINGS SUMMARY: Jefferies Upgrades Hikma To Buy From Hold

LONDON BRIEFING: Barclays, BAT And Sky Gain Following Updates

London close: Investors play it safe ahead of Fed meeting

(ShareCast News) - The selling pressure let up ahead of the start of a two-day policy meeting from the US Federal Reserve, with some investors braced in case the post-meeting statement sprang any surprises. The FTSE 100 finished the session higher by 0.77% to the 6,555.28 mark, alongside a similar b

LONDON MARKET CLOSE: Stocks Rebound; RSA Surges On Zurich's Interest

FTSE 100 movers: RSA rockets, Hikma higher

(ShareCast News) - London's primary index was holding onto its gain by mid-afternoon on Tuesday, boosted by deals and deal talk. At 1415 BST, the FTSE 100 was up 0.81% to 6,557.62, with only a dozen of the blue chip constituents in the red. As soon as markets opened, RSA Insurance moved to the top

UPDATE: Hikma Pharmaceuticals To Buy Roxane Units For USD2.65 Billion (ALLISS)